MedTrace Logo

Statins for the Treatment of NASH

NCT04679376 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-01-20

No results posted yet for this study

Summary

The purpose of this research study is to determine whether the study drug, atorvastatin (Lipitor®), is safe and effective in improving the features of NASH.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

Atorvastatin

40 mg daily administered orally in tablet or capsule form

DRUG

Placebo

Administered daily orally in tablet or capsule form, contains no active medicine

Sponsors & Collaborators

Principal Investigators

  • Manal Abdelmalek, MD, MPH · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-25
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679376 on ClinicalTrials.gov